NASDAQ:ALQA - Alliqua Biomedical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.61 +0.30 (+4.76 %)
(As of 05/26/2019 04:00 PM ET)
Previous Close$6.6074
Today's Range$6.17 - $6.7166
52-Week Range$1.55 - $5.24
Volume5,854 shs
Average Volume114,400 shs
Market Capitalization$33.10 million
P/E RatioN/A
Dividend YieldN/A
Alliqua BioMedical, Inc. develops, manufactures, and markets high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It also provides contract manufacturing services to the OEM market. The company is headquartered in Langhorne, Pennsylvania.

Receive ALQA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALQA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:ALQA



Sales & Book Value

Annual Sales$2.22 million
Book Value$1.65 per share


Net Income$-8,420,000.00
Net Margins-230.50%


Market Cap$33.10 million
Next Earnings DateN/A
OptionableNot Optionable

Alliqua Biomedical (NASDAQ:ALQA) Frequently Asked Questions

What is Alliqua Biomedical's stock symbol?

Alliqua Biomedical trades on the NASDAQ under the ticker symbol "ALQA."

When did Alliqua Biomedical's stock split? How did Alliqua Biomedical's stock split work?

Shares of Alliqua Biomedical reverse split before market open on Friday, October 6th 2017. The 1-10 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of Alliqua Biomedical stock prior to the reverse split would have 10 shares after the split.

How were Alliqua Biomedical's earnings last quarter?

Alliqua Biomedical Inc (NASDAQ:ALQA) released its quarterly earnings results on Tuesday, August, 9th. The company reported $0.50 earnings per share for the quarter, beating the Zacks' consensus estimate of ($2.70) by $3.20. The company had revenue of $5.50 million for the quarter, compared to analysts' expectations of $5.38 million. Alliqua Biomedical had a negative return on equity of 71.73% and a negative net margin of 230.50%. View Alliqua Biomedical's Earnings History.

What is the consensus analysts' recommendation for Alliqua Biomedical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alliqua Biomedical in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alliqua Biomedical.

Has Alliqua Biomedical been receiving favorable news coverage?

News stories about ALQA stock have trended somewhat negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alliqua Biomedical earned a news impact score of -1.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of Alliqua Biomedical's key competitors?

What other stocks do shareholders of Alliqua Biomedical own?

Who are Alliqua Biomedical's key executives?

Alliqua Biomedical's management team includes the folowing people:
  • Mr. David Ian Johnson, Pres, CEO, Principal Financial Officer & Director (Age 61)
  • Dr. Phillip D. Forman M.D., DPM, Exec. VP of Clinical Affairs (Age 60)
  • Mr. Joseph M. Warusz, CFO, Treasurer & Sec. (Age 63)

Who are Alliqua Biomedical's major shareholders?

Alliqua Biomedical's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.76%), Dimensional Fund Advisors LP (0.35%), Private Advisor Group LLC (0.24%) and Acadian Asset Management LLC (0.21%). View Institutional Ownership Trends for Alliqua Biomedical.

Which major investors are buying Alliqua Biomedical stock?

ALQA stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, Private Advisor Group LLC and Acadian Asset Management LLC. View Insider Buying and Selling for Alliqua Biomedical.

How do I buy shares of Alliqua Biomedical?

Shares of ALQA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alliqua Biomedical's stock price today?

One share of ALQA stock can currently be purchased for approximately $6.6074.

How big of a company is Alliqua Biomedical?

Alliqua Biomedical has a market capitalization of $33.10 million and generates $2.22 million in revenue each year. Alliqua Biomedical employs 6 workers across the globe.

What is Alliqua Biomedical's official website?

The official website for Alliqua Biomedical is

How can I contact Alliqua Biomedical?

Alliqua Biomedical's mailing address is 2150 CABOT BLVD WEST SUITE B, LANGHORNE PA, 19047. The company can be reached via phone at 215-702-8550 or via email at [email protected]

MarketBeat Community Rating for Alliqua Biomedical (NASDAQ ALQA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  485
MarketBeat's community ratings are surveys of what our community members think about Alliqua Biomedical and other stocks. Vote "Outperform" if you believe ALQA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALQA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/26/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel